Takeda forecasts significant operating loss for FY2019

14 May 2019

Takeda (TYO: 4502) today presented results for the 2018 financial year ended March 2019, and warned it expects to post a significant operating loss in its coming financial year, due to the integration costs associated with its $62 billion acquisition of Shire.

The negative forecast was unexpected but, notwithstanding, the firm’s shares closed the day down just 0.25% lower at 4,307 yen.

Japan’s largest drugmaker forecast on Tuesday that operating losses in the year to March 2020 will come in at 193 billion yen ($1.8 billion), versus an operating profit of 205 billion in the 12 months to March 2019. The expected loss is substantially below the 200 billion yen operating profit forecast in a Bloomberg poll of 14 analysts.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK